<!DOCTYPE html>
<html>
<head>
    <meta charset="UTF-8">
    <title>Extracted Document</title>
    <style>
        body { font-family: Arial, sans-serif; max-width: 900px; margin: 0 auto; padding: 20px; }
        h1, h2, h3 { color: #333; }
        .page { margin-bottom: 50px; border-bottom: 2px solid #ccc; padding-bottom: 30px; }
        .title { font-size: 1.3em; font-weight: bold; margin: 20px 0; }
        .text { margin: 15px 0; line-height: 1.6; }
        .figure { margin: 20px 0; text-align: center; }
        .figure img { max-width: 100%; height: auto; border: 1px solid #ddd; }
        .figure-caption { font-style: italic; color: #666; margin-top: 10px; }
        .metadata { background: #f5f5f5; padding: 15px; margin-top: 30px; }
    </style>
</head>
<body>

<h1>Extracted Document</h1>
<p><strong>Source:</strong> data/clinical_files/Treanor et al. (2011).pdf</p>
<p><strong>Total Pages:</strong> 7</p>
<hr>
<div class="page">
<h2>Page 1</h2>
<div class="figure">
<img src="figures/figure_p1_e895b74d.png" alt="[FIGURE 1 - See figure_p1_e895b74d.png]" style="max-width: 800px;">
<div class="figure-caption">[FIGURE 1 - See figure_p1_e895b74d.png]</div>
</div>
<div class="title">Protective
 efﬁcacy
 of
 a
 trivalent
 recombinant
 hemagglutinin
 protein
 vaccine
(FluBlok®)
 against
 inﬂuenza
 in
 healthy
 adults:
 A
 randomized,
 placebo-controlled
trial</div>
<div class="text">n<br> J.<br> Treanor<br>,  Hana<br> El  Sahly , James<br> King ,  Irene<br> Graham ,  Ruvim<br> Izikson ,  Robert<br> Kohberger ,<br>er  Patriarca g, Manon<br> Cox e</div>
<div class="text">University<br> of<br> Rochester,<br> Rochester,<br> NY,<br> United<br> States<br>aylor<br> College<br> of<br> Medicine,<br> Houston,<br> TX,<br> United<br> States<br>University<br> of<br> Maryland,<br> Baltimore,<br> MD,<br> United<br> States<br>t.<br> Louis<br> University,<br> St.<br> Louis,<br> MO,<br> United<br> States<br>rotein<br> Sciences<br> Corporation,<br> Meriden,<br> CT,<br> United<br> States<br>lair<br> &<br> Co,<br> Greenwich,<br> CT,<br> United<br> States<br>iologics<br> Consulting<br> Group,<br> Inc.,<br> Bethesda,<br> MD,<br> United<br> States</div>
<div class="title">None</div>
<div class="text">g<br>p<br>y<br>gg<br>cine<br> production<br> is  a high  priority.<br> We  conducted<br> this  study<br> to determine<br> the  protective<br> efﬁcacy<br> a<br>ombinant,<br> baculovirus-expressed<br> seasonal<br> trivalent<br> inﬂuenza<br> virus  hemagglutinin<br> (rHA0)<br> vaccine<br>uBlok®).<br>thods:<br> Healthy<br> adult  subjects<br> at 24  centers<br> across<br> the  US<br> were  randomly<br> assigned<br> to  receive  a single<br>ection<br> of saline  placebo<br> (2304  subjects),<br> or trivalent<br> FluBlok<br> containing<br> 45  mcg  of  each<br> rHA0  component<br>44<br> subjects).<br> Serum  samples<br> for  assessment<br> of  immune<br> responses<br> by  hemagglutination-inhibition<br>AI)<br> were  taken  from  a subset  of subjects<br> before<br> and 28  days  after  immunization.<br> Subjects  were<br> followed<br>ing<br> the  2007–2008<br> inﬂuenza<br> season<br> and  combined<br> nasal  and  throat  swabs<br> for  virus  isolation<br> were<br>ained<br> from  subjects<br> reporting<br> inﬂuenza-like<br> illness.<br>ults: Rates of local and systemic side effects were low and the rates of systemic side effects were</div>
<div class="text">sults:<br> Rates  of local  and  systemic<br> side  effects  were  low,  and  the  rates  of systemic<br> side  effects<br> were<br>milar<br> in the  vaccine<br> and  placebo<br> groups.<br> HAI  antibody<br> responses<br> were  seen<br> in  78%,  81%,  and  52%  of<br>Blok<br> recipients<br> to  the  H1,  H3,  and  B  components,<br> respectively.<br> FluBlok<br> was<br> 44.6%  (95% CI, 18.8%,<br>6%)<br> effective  in  preventing<br> culture-conﬁrmed<br> inﬂuenza<br> meeting<br> the  CDC  inﬂuenza-like  illness  case<br>ﬁnition<br> despite<br> signiﬁcant<br> antigenic<br> mismatch<br> between<br> the  vaccine<br> antigens<br> and<br> circulating<br> viruses.<br>nclusions:<br> Trivalent<br> rHA0<br> vaccine<br> was  safe,  immunogenic<br> and  effective  in  the  prevention<br> of  culture<br>nﬁrmed<br> inﬂuenza<br> illness,<br> including<br> protection<br> against  drift  variants.<br>© 2011 Elsevier Ltd All rights reserved</div>
<div class="title">None</div>
<div class="text">Although<br> embryonated<br> hen s<br> eggs<br> have<br> been<br> used<br> to<br> generate<br>fective<br> inﬂuenza<br> vaccines<br> for<br> many<br> years,<br> this<br> system<br> does<br> have<br>veral<br> important<br> drawbacks.<br> Vaccine<br> manufacturing<br> using<br> eggs<br>quires<br> specialized<br> facilities,<br> and<br> the<br> ability<br> to<br> scale<br> up<br> egg<br> pro-<br>uction<br> rapidly<br> in<br> response<br> to<br> an<br> emergency<br> is<br> limited.<br> In<br> addition,<br>oultry<br> are<br> potentially<br> vulnerable<br> to<br> the<br> same<br> subtypes<br> of<br> inﬂuenza</div>
<div class="text">∗Corresponding<br> author<br> at:<br> University<br> of<br> Rochester<br> Medical<br> Center,<br> Room<br> 3-6308,<br>1<br> Elmwood<br> Avenue,<br> Rochester,<br> NY<br> 14642,<br> United<br> States.<br> Tel.:<br> +1<br> 585<br> 275<br> 5871;<br>x:<br> +1<br> 585<br> 442<br> 9328.<br>E-mail<br> address:<br> John Treanor@urmc.rochester.edu<br> (J.J.<br> Treanor).</div>
<div class="text">i:10.1016/j.vaccine.2011.07.128</div>
<div class="text">ruses<br> that<br> might<br> also<br> be<br> responsible<br> for<br> pandemic<br> inﬂuenza.<br> It<br> is<br>sually<br> necessary<br> to<br> adapt<br> candidate<br> vaccine<br> viruses<br> for<br> high<br> yield<br>rowth<br> in<br> eggs,<br> a<br> process<br> that<br> can<br> be<br> time<br> consuming,<br> is<br> not<br> always<br>uccessful,<br> and<br> which<br> can<br> select<br> receptor<br> variants<br> that<br> may<br> not<br> be<br>ptimally<br> representative<br> of<br> circulating<br> inﬂuenza<br> strains<br> [1,2].<br>Expression<br> of<br> proteins<br> in<br> insect<br> cells<br> using<br> recombinant<br> bac-<br>ovirus<br> has<br> emerged<br> as<br> a<br> promising<br> technology<br> for<br> vaccine<br>roduction.<br> New<br> recombinant<br> baculoviruses<br> can<br> be<br> generated<br>uickly<br> from<br> sequence<br> data,<br> protein<br> expression<br> is<br> very<br> efﬁcient<br>nder<br> the<br> control<br> of<br> the<br> baculovirus<br> polyhedrin<br> promoter,<br> and<br> post<br>anslational<br> modiﬁcations<br> of<br> the<br> protein<br> are<br> generally<br> similar<br> to<br>ther<br> eukaryotic<br> systems.<br> In<br> previous<br> studies,<br> we<br> have<br> evaluated<br>aculovirus-expressed<br> recombinant<br> inﬂuenza<br> virus<br> hemagglu-<br>nins<br> (rHA0s)<br> as<br> inﬂuenza<br> vaccines<br> in<br> humans.<br> Monovalent<br> and<br>valent<br> rHA0s<br> have<br> been<br> well<br> tolerated<br> and<br> immunogenic<br> in</div>
</div>
<div class="page">
<h2>Page 2</h2>
<div class="text">oung<br> adults<br> and<br> adults<br> 65<br> and<br> older<br> [3 5].<br> More<br> recent<br> stud<br>s<br> have<br> evaluated<br> rHA0<br> vaccine<br> formulations<br> in<br> healthy<br> adults,<br>ubjects<br> aged<br> 50–64<br> years<br> of<br> age<br> [6]<br> and<br> subjects<br> 65<br> and<br> older<br>7,8].<br> These<br> studies<br> have<br> consistently<br> shown<br> excellent<br> tolerabil-<br>y<br> and<br> antibody<br> responses<br> similar<br> to<br> those<br> seen<br> with<br> egg-derived<br>nﬂuenza<br> vaccines.<br> Finally,<br> in<br> a<br> preliminary<br> ﬁeld<br> efﬁcacy<br> eval-<br>ation,<br> recipients<br> of<br> the<br> rHA0<br> vaccine<br> had<br> reduced<br> rates<br> of<br>ulture-positive<br> CDC-deﬁned<br> inﬂuenza-like<br> illness<br> compared<br> with<br>lacebo<br> recipients,<br> although<br> the<br> study<br> was<br> small<br> [9].<br>In<br> the<br> present<br> study,<br> we<br> performed<br> a<br> much<br> larger<br> assessment<br>f<br> the<br> immunogenicity,<br> safety,<br> and<br> protective<br> efﬁcacy<br> of<br> the<br> ﬁnal<br>ormulation<br> of<br> trivalent<br> rHA0<br> vaccine<br> in<br> a<br> population<br> of<br> healthy<br>oung<br> adults.</div>
<div class="title">None</div>
<div class="title">None</div>
<div class="text">The<br> vaccine<br> (FluBlok)<br> used<br> in<br> this<br> study<br> consisted<br> of<br> puri<br>ed<br> hemagglutinin<br> (HA)<br> proteins<br> produced<br> in<br> insect<br> cells<br> using<br>baculovirus<br> expression<br> system<br> as<br> previously<br> described<br> [9].  The<br>combinant<br> HA<br> protein<br> is<br> not<br> cleaved<br> in<br> insect<br> cells<br> and<br> is<br>ferred<br> to<br> as<br> rHA0.<br> The<br> trivalent<br> vaccine<br> contained<br> 45<br> mcg<br>s<br> measured<br> by<br> the<br> single<br> radial<br> immunodiffusion<br> assay)<br> of<br>ach<br> puriﬁed<br> rHA0<br> derived<br> from<br> the<br> A/Solomon<br> Islands/3/2006<br>H1N1),<br> A/Wisconsin/67/2005<br> (H3N2),<br> and<br> B/Malaysia/2506/2004<br>ﬂuenza<br> viruses<br> recommended<br> for<br> the<br> 2007–2008<br> inﬂuenza<br>ason<br> formulated<br> with<br> 0.005%<br> Tween®-20<br> in<br> 10<br> mM sodium<br>hosphate<br> buffer<br> pH<br> 7.0<br> ±<br> 0.4<br> without<br> a<br> preservative.<br> Genes<br>ere<br> cloned<br> into<br> baculovirus<br> using<br> RT-PCR<br> from<br> the<br> same<br> CDC-<br>erived<br> vaccine<br> seed<br> viruses<br> used<br> for<br> the<br> production<br> of<br> licensed<br>activated<br> inﬂuenza<br> vaccine<br> for<br> that<br> year.<br> Sodium<br> dodecyl<br> sulfate-<br>olyacrylamide<br> gel<br> electrophoresis<br> of<br> the<br> puriﬁed<br> monovalent<br>aterials<br> indicated<br> that<br> hemagglutinin<br> constitutes<br> at<br> least<br> 90%<br> of<br>e<br> total<br> protein.<br> Placebo<br> consisted<br> of<br> normal<br> saline<br> for<br> injection,<br>SP.</div>
<div class="title">y
g</div>
<div class="text">The<br> study<br> was<br> conducted<br> at<br> 24<br> centers<br> located<br> across<br> the<br> United<br>ates<br> (Appendix)<br> during<br> the<br> 2007–2008<br> inﬂuenza<br> season.<br> Subjects<br>ere<br> healthy<br> adults<br> aged<br> 18–49<br> years<br> inclusive,<br> who<br> did<br> not<br> belong<br> high<br> priority<br> target<br> groups<br> for<br> inﬂuenza<br> vaccination<br> as<br> deﬁned<br>y<br> the<br> Advisory<br> Committee<br> on<br> Immunization<br> Practice<br> [10]. Women<br> child-bearing<br> potential<br> had<br> a<br> negative<br> urine<br> pregnancy<br> test<br> at<br>he<br> time<br> of<br> randomization<br> and<br> were<br> instructed<br> to<br> use<br> contracep-<br>on<br> during<br> the<br> course<br> of<br> the<br> study.<br> After<br> screening<br> medical<br> history<br>nd<br> physical<br> exam<br> to<br> determine<br> eligibility,<br> subjects<br> were<br> randomly<br>signed<br> to<br> receive<br> either<br> a<br> single<br> dose<br> of<br> FluBlok,<br> or<br> saline<br> placebo<br>sing<br> a<br> permuted<br> block<br> randomization<br> scheme<br> stratiﬁed<br> for<br> each<br>udy<br> site.<br> Vaccine<br> was<br> administered<br> as<br> a<br> single<br> intramuscular<br>jection<br> in<br> the<br> upper<br> deltoid.<br>Subjects<br> measured<br> their<br> oral<br> temperature<br> daily<br> and<br> maintained<br>memory<br> aid<br> for<br> 7<br> days<br> after<br> vaccination<br> on<br> which<br> they<br> recorded<br>cal<br> and<br> systemic<br> reactions<br> graded<br> as<br> “mild”<br> (noticeable<br> but<br> not<br>terfering<br> with<br> normal<br> activities),<br> “moderate”<br> (some<br> interference<br>ith<br> normal<br> activities),<br> and<br> “severe”<br> (symptom<br> prevented<br> nor-<br>al<br> daily<br> activities).<br> Subjects<br> received<br> a<br> phone<br> call<br> at<br> day<br> 7<br> for<br>view<br> of<br> the<br> memory<br> aid,<br> concomitant<br> medications<br> and<br> medical<br>story.<br>In addition<br>subjects from ﬁve sites (total<br>N = 870) partici-</div>
<div class="text">In<br> addition,<br> subjects<br> from<br> ﬁve<br> sites<br> (total,<br> N<br> <br> 870)<br> partici<br>ted<br> in<br> a<br> serological<br> substudy.<br> At<br> these<br> sites,<br> subjects<br> had<br> serum<br>tained<br> prior<br> to<br> vaccination,<br> and<br> returned<br> approximately<br> 28<br> days<br>ter<br> vaccination<br> for<br> assessment<br> of<br> serum<br> antibody<br> to<br> inﬂuenza<br>rus.<br> All<br> other<br> subjects<br> received<br> a<br> phone<br> call<br> from<br> their<br> medical</div>
<div class="text">y<br>y<br>p<br>ccurred<br> at<br> the<br> end<br> of<br> the<br> inﬂuenza<br> season.</div>
<div class="title">f
ﬂ</div>
<div class="text">During<br> the<br> inﬂuenza<br> season,<br> subjects<br> completed<br> a<br> weekly<br> diary<br>o<br> record<br> inﬂuenza<br> symptoms,<br> and<br> after<br> inﬂuenza<br> was<br> recognized<br> the<br> community,<br> subjects<br> received<br> weekly<br> phone<br> calls<br> to<br> review<br>he<br> diary<br> and<br> ascertain<br> the<br> presence<br> or<br> absence<br> of<br> respiratory<br> ill-<br>ess<br> symptoms.<br> Subjects<br> were<br> instructed<br> to<br> return<br> to<br> the<br> clinic<br> for<br>ness<br> evaluations<br> if<br> they<br> observed<br> any<br> acute<br> respiratory<br> symp-<br>oms<br> or<br> fever.<br> During<br> these<br> illness<br> visits,<br> symptoms<br> were<br> reviewed,<br>brief<br> physical<br> exam<br> was<br> conducted,<br> and<br> combined<br> nasal<br> and<br>hroat<br> swabs<br> for<br> virus<br> culture<br> were<br> obtained.</div>
<div class="title">y
y</div>
<div class="text">Sera<br> from<br> the<br> immunogenicity<br> subset<br> were<br> assessed<br> for<br>ntibody<br> to<br> each<br> of<br> the<br> three<br> components<br> of<br> the<br> vaccine<br> by<br>emagglutination-inhibition<br> (HAI)<br> at<br> the<br> Cincinnati<br> Children’s<br>ospital<br> using<br> a<br> validated<br> assay<br> based<br> on<br> standard<br> methods.<br> All<br>vailable<br> sera<br> from<br> vaccine<br> recipients,<br> and<br> a<br> randomly<br> selected<br>ubset<br> of<br> approximately<br> 33%<br> of<br> placebo<br> specimens<br> were<br> selected<br>r<br> testing.<br> The<br> antigens<br> used<br> in<br> the<br> assays<br> were<br> baculovirus<br>erived<br> rHAs<br> representing<br> the<br> A/Solomon<br> Islands/03/2006<br> (H1N1),<br>/Wisconsin/67/2005<br> (H3N2),<br> and<br> B/Malaysia/2506/2004<br> viruses,<br>rovided<br> by<br> Protein<br> Sciences<br> Corporation.<br> Sera<br> were<br> treated<br> with<br>euraminidase<br> (RDE,<br> Denka-Seiken,<br> Japan)<br> to<br> remove<br> non-speciﬁc<br>hibitors<br> of<br> hemagglutination<br> prior<br> to<br> testing,<br> and<br> were<br> tested<br> in<br>rial<br> two-fold<br> dilutions<br> at<br> an<br> initial<br> dilution<br> of<br> 1:10.<br> Sera<br> with<br>o<br> reactivity<br> at<br> 1:10<br> were<br> assigned<br> a<br> value<br> of<br> 1:5.<br> Assays<br> were<br>erformed<br> using<br> turkey<br> red<br> blood<br> cells<br> (Viromed<br> Laboratories,<br> Min-<br>etonka,<br> MN).<br>Swabs<br> for<br> virus<br> culture<br> were<br> stored<br> at<br> −70 ◦C<br> and<br> shipped<br> on<br>ry<br> ice<br> to<br> a<br> central<br> laboratory<br> (Cincinnati<br> Children’s<br> Hospital<br> Med-<br>al<br> Center,<br> Cincinnati,<br> OH)<br> where<br> virus<br> isolation<br> was<br> performed<br> in<br>rimary<br> rhesus<br> monkey<br> kidney<br> (RhMK)<br> cells<br> (Diagnostic<br> Hybrids<br>c<br> (DHI),<br> Athens,<br> Ohio).<br> The<br> presence<br> of<br> inﬂuenza<br> A<br> or<br> B<br> viruses<br>the<br> culture<br> was<br> determined<br> by<br> immunoﬂuorescence<br> using<br> type-<br>peciﬁc<br> monoclonal<br> antibodies<br> (DHI).<br> All<br> inﬂuenza<br> isolates<br> were<br>ubsequently<br> subtyped<br> and<br> antigenically<br> characterized<br> based<br> on<br>activity<br> to<br> ferret<br> antiserum<br> raised<br> against<br> WHO<br> reference<br> strains.</div>
<div class="title">y</div>
<div class="text">The<br> primary<br> safety<br> endpoints<br> for<br> this<br> study<br> were<br> the<br> rates<br>nd<br> severity<br> of<br> solicited<br> and<br> unsolicited<br> adverse<br> events.<br> The<br> pri-<br>ary<br> immunogenicity<br> endpoints<br> were<br> the<br> rates<br> of<br> 4-fold<br> or<br> greater<br>creases<br> in<br> serum<br> HAI<br> antibody<br> to<br> each<br> of<br> the<br> three<br> vaccine<br>rains<br> comparing<br> pre-<br> and<br> 28-day<br> post-vaccination<br> samples.<br> The<br>rimary<br> efﬁcacy<br> endpoint<br> was<br> culture-documented<br> inﬂuenza<br> ill-<br>ess,<br> deﬁned<br> as<br> development<br> of<br> a<br> CDC-deﬁned<br> inﬂuenza-like<br>ness<br> (CDC-ILI)<br> associated<br> with<br> recovery<br> of<br> inﬂuenza<br> virus<br> from<br>nasopharyngeal<br> swab.<br> CDC-ILI<br> was<br> deﬁned<br> as<br> the<br> presence<br> of<br>ocumented<br> fever<br> ≥100<br> F<br> plus<br> either<br> sore<br> throat<br> or<br> cough.<br>Safety<br> of<br> the<br> rHA0<br> vaccine<br> was<br> evaluated<br> via<br> the<br> frequencies<br>nd<br> percentages<br> of<br> subjects<br> experiencing<br> adverse<br> events,<br> and<br> a<br>hi-squared<br> test<br> at<br> a<br> nominal<br> 0.05<br> level<br> was<br> performed<br> to<br> ﬁnd<br>ny<br> differences<br> in<br> incidence<br> rates<br> between<br> groups.<br> Differences<br>etween<br> groups<br> in<br> the<br> proportions<br> of<br> subjects<br> with<br> at<br> least<br> a<br> four-<br>ld<br> increase<br> in<br> HAI<br> antibody<br> were<br> also<br> tested<br> using<br> a<br> Chi-Square<br>st.<br> Protective<br> efﬁcacy<br> (PE)<br> was<br> calculated<br> as<br> (1-RR),<br> where<br> RR<br> is<br>e<br> relative<br> risk<br> of<br> having<br> an<br> event<br> compared<br> to<br> the<br> placebo<br> group.<br>pper<br> and<br> lower<br> conﬁdence<br> limits<br> for<br> the<br> RR<br> were<br> calculated<br> using<br>e<br> exact<br> conditional<br> binomial<br> procedure.</div>
</div>
<div class="page">
<h2>Page 3</h2>
<div class="title">tes
 of
 lo</div>
<div class="text">mptoms<br>No (%) of subjects<br>ith complaints b<br>le el of se eri</div>
<div class="figure">
<img src="figures/table_p3_5bbb19f2.png" alt="[TABLE 3 - See table_p3_5bbb19f2.png]" style="max-width: 800px;">
<div class="figure-caption">[TABLE 3 - See table_p3_5bbb19f2.png]</div>
</div>
<div class="text">nd<br> 3<br> =<br> severe,<br> prevents<br> normal<br> daily<br> activity.<br>* P<br> <<br> .05<br> compared<br> to<br> placebo.</div>
<div class="text">p<br>y<br>p<br>on<br> that<br> FluBlok<br> would<br> be<br> at<br> least<br> 70%<br> efﬁcacious<br> in<br> prevention<br> of<br>mptomatic,<br> culture-proven<br> inﬂuenza,<br> and<br> that<br> the<br> placebo<br> attack<br>te<br> would<br> be<br> 3%<br> or<br> greater.<br> The<br> sample<br> size<br> was<br> then<br> chosen<br> to<br>ve<br> 80%<br> power<br> to<br> determine<br> that<br> the<br> lower<br> bound<br> of<br> the<br> 95%<br>nﬁdence<br> interval<br> for<br> protective<br> efﬁcacy<br> was<br> greater<br> than<br> 40%,<br>suming<br> a<br> 5%<br> attrition<br> rate.</div>
<div class="title">f</div>
<div class="text">j<br>e<br> study,<br> and<br> the<br> study<br> was<br> approved<br> by<br> the<br> institutional<br> review<br>ards<br> at<br> each<br> study<br> site<br> prior<br> to<br> initiation<br> of<br> the<br> study<br> and<br> enroll-<br>ent<br> of<br> subjects.</div>
<div class="title">None</div>
<div class="text">tota o<br>6 8 e g b e subjects<br>e e a do<br>ed<br>:<br>to ece<br>e<br>her<br> FluBlok<br> or<br> Placebo,<br> and<br> 4071<br> (87.5%)<br> completed<br> all<br> study<br>ocedures.<br> The<br> disposition<br> of<br> the<br> study<br> subjects<br> is<br> shown<br> in<br>g.<br> 1.<br> Of<br> the<br> 4648<br> enrolled<br> subjects,<br> 2344<br> were<br> randomized<br> to</div>
<div class="figure">
<img src="figures/figure_p3_e24f87e5.png" alt="[FIGURE 10 - See figure_p3_e24f87e5.png]" style="max-width: 800px;">
<div class="figure-caption">[FIGURE 10 - See figure_p3_e24f87e5.png]</div>
</div>
<div class="text">ceive<br> FluBlok<br> and<br> 2304<br> were<br> randomized<br> to<br> placebo.<br> The<br> major<br>y<br> of<br> subjects<br> were<br> white<br> (66%)<br> and<br> female<br> (59%).<br> The<br> mean<br> age<br>as<br> 32.5<br> years.<br> Three<br> subjects<br> were<br> over<br> the<br> enrollment<br> criteria<br> of<br>9<br> years<br> or<br> less,<br> so<br> that<br> the<br> age<br> range<br> enrolled<br> was<br> 18–55<br> years;<br>ese<br> three<br> subjects<br> are<br> included<br> in<br> both<br> the<br> safety<br> and<br> efﬁcacy<br>nalyses.<br> There<br> were<br> no<br> differences<br> with<br> respect<br> to<br> age,<br> sex<br> or<br> race<br>etween<br> the<br> groups.<br>There<br> were<br> 577<br> subjects<br> who<br> did<br> not<br> complete<br> the<br> study,<br> the<br>ajority<br> of<br> whom<br> were<br> lost<br> to<br> follow-up<br> (260<br> (11%)<br> in<br> the<br> FluBlok<br>nd<br> 251<br> (11%)<br> in<br> the<br> placebo<br> group).<br> In<br> addition,<br> 36<br> subjects<br>ithdrew<br> consent<br> (22<br> (1%)<br> and<br> 14<br> (0.6%)<br> in<br> FluBlok<br> and<br> placebo,<br>spectively),<br> 3<br> in<br> each<br> group<br> withdrew<br> due<br> to<br> an<br> adverse<br> event<br>AE),<br> there<br> was<br> 1<br> death<br> in<br> each<br> group,<br> and<br> 9<br> and<br> 13<br> subjects<br> in<br>e<br> FluBlok<br> and<br> placebo<br> groups,<br> respectively<br> were<br> discontinued<br> for<br>her<br> reasons.</div>
<div class="title">f
f
y</div>
<div class="text">ported<br> by<br> subjects<br> in<br> the<br> 7<br> days<br> following<br> administration<br> of<br>uBlok<br> or<br> placebo<br> are<br> shown<br> in<br> Table<br> 1.<br> FluBlok<br> was<br> associated<br>ith<br> local<br> injection<br> site<br> pain<br> and<br> muscle<br> aches<br> that<br> were<br> signif-<br>antly<br> more<br> frequent<br> than<br> after<br> saline<br> placebo<br> (P<br> < .03<br> for<br> pain).<br>owever,<br> 94%<br> of<br> all<br> complaints<br> of<br> pain<br> after<br> FluBlok<br> were<br> rated<br>mild.<br> Systemic<br> symptoms<br> following<br> vaccination<br> did<br> not<br> occur<br>signiﬁcantly<br> different<br> rates<br> in<br> vaccine<br> and<br> placebo<br> recipients<br>><br> .05<br> for<br> all<br> comparisons).<br> The<br> most<br> frequently<br> reported<br> sys-<br>mic<br> symptoms<br> following<br> vaccination<br> were<br> headache<br> (15%<br> in<br> both<br>oups)<br> and<br> fatigue<br> or<br> lack<br> of<br> energy<br> (14.5%<br> in<br> both<br> groups).<br> The<br>ajority<br> (76%)<br> of<br> complaints<br> of<br> headache<br> were<br> also<br> mild.<br> There<br>ere<br> 17<br> reports<br> of<br> fever<br> (oral<br> temperature<br> >100.4<br> F)<br> among<br> FluBlok<br>cipients<br> and<br> 12<br> among<br> placebo<br> recipients<br> following<br> vaccination.<br>There<br> were<br> 85<br> severe<br> adverse<br> events<br> (SAEs)<br> reported<br> during<br> the<br>udy<br> in<br> 64<br> subjects.<br> Of<br> these,<br> 41<br> SAEs<br> were<br> reported<br> in<br> 30<br> subjects<br>.28%)<br> in<br> the<br> FluBlok<br> group,<br> and<br> 44<br> SAEs<br> in<br> 34<br> subjects<br> (1.48%)<br>the<br> placebo<br> group.<br> Two<br> subjects<br> died<br> during<br> the<br> study;<br> one<br> in<br>ach<br> group.<br> A<br> subject<br> in<br> the<br> FluBlok-treatment<br> group<br> experienced<br> a<br>tal<br> pulmonary<br> embolism<br> approximately<br> three<br> months<br> post<br> vacci-<br>ation,<br> and<br> a<br> subject<br> in<br> the<br> placebo<br> group<br> had<br> a<br> fatal<br> motor<br> vehicle<br>cident.<br> Both<br> deaths<br> were<br> considered<br> to<br> be<br> unrelated<br> to<br> the<br> study<br>y<br> the<br> site<br> investigator.<br> All<br> but<br> two<br> SAEs<br> (a<br> liposarcoma<br> in<br> a<br> FluBlok<br>cipient<br> and<br> breast<br> cancer<br> in<br> a<br> placebo<br> recipient)<br> had<br> resolved<br>y<br> the<br> end<br> of<br> the<br> study<br> period.<br> None<br> of<br> the<br> 85<br> SAEs<br> in<br> the<br> study<br>ere<br> considered<br> to<br> be<br> deﬁnitely<br> or<br> probably<br> related<br> to<br> vaccine.<br> One<br>vent,<br> a<br> pericardial<br> effusion<br> in<br> a<br> FluBlok<br> recipient<br> was<br> judged<br> to<br> be<br>ossibly<br> related<br> to<br> vaccine.<br> This<br> event<br> occurred<br> in<br> a<br> 47<br> year-old<br>ale<br> with<br> a<br> prior<br> history<br> of<br> hypertension,<br> who<br> began<br> experiencing</div>
</div>
<div class="page">
<h2>Page 4</h2>
<div class="title">None</div>
<div class="title">rum
 hem</div>
<div class="text">Group<br>N<br>Pre (day 0) and post vaccination (day 28) geometric mean antibody titer (95% CI) and response rates (95% CI) to the following vaccine antigens</div>
<div class="figure">
<img src="figures/table_p4_eeb10c0d.png" alt="[TABLE 4 - See table_p4_eeb10c0d.png]" style="max-width: 800px;">
<div class="figure-caption">[TABLE 4 - See table_p4_eeb10c0d.png]</div>
</div>
<div class="text">PV<br> =<br> previously<br> vaccinated.<br>NPV<br> =<br> not<br> previously<br> vaccinated.</div>
<div class="text">ever<br> and<br> cough<br> 7<br> days<br> after<br> vaccination<br> and<br> was<br> hospitalized<br> 11<br>ays<br> after<br> vaccination<br> with<br> a<br> diagnosis<br> of<br> pericardial<br> effusion<br> and<br>ardiac<br> tamponade.<br> Pericardiocentesis<br> showed<br> one<br> colony<br> of<br> Propi-<br>nibacterium<br> spp.;<br> and<br> culture<br> of<br> pleural<br> ﬂuid<br> grew<br> Staphylococcus<br>pidermidis<br> only.<br> Viral<br> cultures<br> and<br> a<br> panel<br> of<br> serum<br> antibody<br> tests<br>or<br> viruses<br> causing<br> pericarditis<br> were<br> negative.<br> The<br> subject<br> was<br> dis-<br>harged<br> home<br> on<br> Day<br> 24<br> following<br> vaccination<br> and<br> the<br> event<br> was<br>onsidered<br> resolved<br> by<br> the<br> end<br> of<br> the<br> study<br> period.<br>There were a total of 37 pregnancies reported during the study;</div>
<div class="text">e e<br>e e a tota o 3<br>p eg a c es epo ted du<br>g t e study;<br>0<br> in<br> the<br> FluBlok<br> group<br> and<br> 17<br> in<br> the<br> placebo<br> group.<br> Complete<br>llow-up<br> information<br> was<br> available<br> for<br> 30<br> for<br> them<br> (15<br> in<br> FluBlok<br>nd<br> 15<br> in<br> placebo).<br> Ten<br> of<br> the<br> pregnancies<br> among<br> FluBlok<br> and<br> 8<br>mong<br> placebo<br> recipients<br> were<br> uneventful<br> and<br> resulted<br> in<br> the<br> birth<br>a<br> normal<br> infant<br> at<br> 36<br> weeks<br> gestation<br> or<br> later.<br> Two<br> women<br> in<br> the<br>uBlok<br> and<br> three<br> in<br> the<br> placebo<br> group<br> had<br> associated<br> AEs<br> during<br>eir<br> pregnancy<br> which<br> all<br> resolved.<br> Elective<br> or<br> spontaneous<br> abor-<br>on<br> occurred<br> in<br> three<br> and<br> four<br> subjects<br> in<br> the<br> FluBlok<br> and<br> placebo<br>oups,<br> respectively.</div>
<div class="title">g
y</div>
<div class="text">Serum<br> HAI<br> antibody<br> titers<br> before<br> and<br> after<br> immunization<br> in<br>uBlok<br> and<br> placebo<br> recipients<br> are<br> shown<br> in<br> Table<br> 2.<br> FluBlok<br>duced<br> serum<br> antibody<br> responses<br> to<br> all<br> three<br> components<br> of<br> the<br>ccine<br> in<br> the<br> majority<br> of<br> recipients,<br> although<br> lower<br> response<br> rates<br>ere<br> seen<br> for<br> the<br> inﬂuenza<br> B<br> component.<br> As<br> expected,<br> post<br> vac-<br>nation<br> geometric<br> mean<br> titers<br> were<br> substantially<br> higher<br> for<br> all<br>ree<br> components<br> in<br> FluBlok<br> than<br> in<br> placebo<br> recipients<br> (P<br> <<br> .001<br>r<br> all<br> comparisons).<br> The<br> proportion<br> of<br> FluBlok<br> recipients<br> with<br>post-vaccination<br> HAI<br> titer<br> of<br> 1:40<br> or<br> greater<br> was<br> 99%<br> for<br> the<br>1<br> component<br> (95%<br> CI,<br> 97.1%,<br> 99.5%),<br> 97%<br> for<br> the<br> H3<br> component<br>4.8%,<br> 98.3%),<br> and<br> 96%<br> for<br> the<br> B<br> component<br> (94.0%,<br> 97.8%).<br>Among<br> FluBlok<br> recipients,<br> subjects<br> with<br> a<br> self-reported<br> history<br>seasonal<br> inﬂuenza<br> vaccine<br> in<br> the<br> year<br> prior<br> to<br> the<br> study<br> had<br>gher<br> baseline<br> titers<br> of<br> antibody<br> against<br> all<br> three<br> components,<br> and<br>d<br> signiﬁcantly<br> lower<br> frequencies<br> of<br> HAI<br> response<br> than<br> did<br> those<br>ho<br> reported<br> that<br> they<br> had<br> not<br> received<br> vaccine<br> in<br> the<br> previous<br>ar.<br> Subjects<br> who<br> reported<br> prior<br> vaccine<br> receipt<br> also<br> had<br> lower<br>ost<br> vaccination<br> GMTs<br> for<br> all<br> three<br> components<br> than<br> did<br> those<br>ithout<br> this<br> history,<br> and<br> this<br> difference<br> was<br> statistically<br> signiﬁcant<br>r<br> both<br> inﬂuenza<br> A<br> components.</div>
<div class="title">fﬁ
y</div>
<div class="text">Subjects<br> in<br> this<br> study<br> were<br> followed<br> throughout<br> the<br> subsequent<br>ﬂuenza<br> season<br> (mid<br> December<br> 2007<br> to<br> end<br> April<br> 2008)<br> with<br>eekly<br> phone<br> calls<br> and<br> instructed<br> to<br> return<br> to<br> the<br> study<br> clinics<br>r<br> any<br> acute<br> respiratory<br> illness,<br> at<br> which<br> time<br> a<br> combined<br> nasal<br>d<br> throat<br> swab<br> for<br> viral<br> culture<br> was<br> obtained.<br> The<br> primary<br> efﬁcacy</div>
<div class="text">p<br>y<br>p<br>DC-ILI,<br> and<br> we<br> also<br> assessed<br> the<br> effect<br> of<br> vaccination<br> on<br> rates<br> of<br>ny<br> inﬂuenza<br> culture<br> positive<br> illness.<br>A total<br> of<br> 582<br> subjects<br> were<br> cultured<br> for<br> respiratory<br> illness,<br> and<br>nﬂuenza<br> virus<br> was<br> isolated<br> from<br> 178<br> subjects.<br> There<br> were<br> a<br> total<br>f<br> 120<br> subjects<br> from<br> whom<br> inﬂuenza<br> A<br> was<br> isolated,<br> the<br> majority<br>f<br> whom<br> (82/120,<br> 68%)<br> met<br> the<br> CDC-ILI<br> case<br> deﬁnition.<br> There<br> were<br>total<br> of<br> 59<br> subjects<br> with<br> positive<br> cultures<br> for<br> inﬂuenza<br> B,<br> and<br> the<br>majority<br> of<br> these<br> subjects<br> (41/59,<br> 69%)<br> also<br> met<br> the<br> CDC-ILI<br> case<br>eﬁnition.<br>Only<br> 8<br> isolates<br> in<br> the<br> study<br> (<5%<br> of<br> the<br> total)<br> were<br> antigeni-<br>ally<br> identical<br> to<br> the<br> strains<br> contained<br> in<br> the<br> vaccine.<br> All<br> of<br> these<br>iruses<br> were<br> A/Wisconsin/67/2005-like<br> H3N2<br> viruses.<br> Two<br> of<br> these<br>ccurred<br> in<br> FluBlok<br> recipients<br> and<br> 6<br> occurred<br> in<br> placebo<br> recipi-<br>nts,<br> and<br> among<br> these<br> subjects<br> one<br> FluBlok<br> recipient<br> and<br> 5<br> placebo<br>ecipients<br> met<br> the<br> CDC-ILI<br> deﬁnition.<br> Therefore,<br> we<br> were<br> unable<br>o<br> obtain<br> a<br> meaningful<br> estimate<br> of<br> the<br> efﬁcacy<br> of<br> FluBlok<br> against<br>DC-ILI<br> due<br> to<br> strains<br> represented<br> in<br> the<br> vaccine.<br>The<br> remaining<br> 111<br> inﬂuenza<br> A<br> viruses<br> were<br> characterized<br> as<br>ntigenic<br> variants,<br> i.e.,<br> they<br> exhibited<br> a<br> 4-fold<br> or<br> greater<br> decrease<br>n<br> reactivity<br> with<br> post<br> infection<br> ferret<br> antisera<br> in<br> reciprocal<br> HAI<br>esting.<br> These<br> viruses<br> included<br> 12<br> H1N1<br> viruses<br> antigenically<br>esembling<br> H1<br> drift<br> variant<br> A/Brisbane/59/2007,<br> 41<br> H3N2<br> viruses<br>ntigenically<br> resembling<br> the<br> H3<br> drift<br> variant<br> A/Brisbane/10/2007,<br>2<br> H3N2<br> viruses<br> that<br> could<br> not<br> be<br> identiﬁed<br> as<br> either<br> A/Wisconsin-<br>ke<br> or<br> A/Brisbane-like,<br> and<br> 16<br> inﬂuenza<br> viruses<br> for<br> which<br> the<br>ubtype<br> was<br> not<br> determined.<br> Fifty-eight<br> of<br> the<br> 59<br> inﬂuenza<br> B<br>iruses<br> (98%)<br> were<br> antigenically<br> similar<br> to<br> B/Florida/04/2006,<br>epresenting<br> a<br> different<br> clade<br> from<br> the<br> vaccine<br> strain,<br> and<br> one<br>nﬂuenza<br> B<br> virus<br> could<br> not<br> be<br> antigenically<br> characterized.<br>The<br> cumulative<br> rates<br> of<br> culture<br> conﬁrmed<br> inﬂuenza<br> illness<br>ccurring<br> in<br> the<br> study<br> population<br> over<br> time<br> are<br> shown<br> in<br> Fig.<br> 2,<br>which<br> shows<br> that<br> the<br> relative<br> difference<br> between<br> the<br> two<br> study<br>roups<br> remained<br> constant<br> throughout<br> the<br> inﬂuenza<br> season.<br> The<br>ncidence<br> of<br> this<br> and<br> of<br> other<br> related<br> endpoints<br> in<br> the<br> study<br> by<br>roup<br> are<br> shown<br> in<br> Table<br> 3.<br> The<br> overall<br> protective<br> efﬁcacy<br> of<br>luBlok<br> against<br> culture<br> positive<br> CDC-ILI<br> regardless<br> of<br> strain<br> was<br>4.6%<br> (95%<br> CI<br> 18.8%,<br> 62.6%).<br> As<br> expected<br> given<br> the<br> more<br> extreme<br>egree<br> of<br> antigenic<br> mismatch<br> for<br> the<br> inﬂuenza<br> B<br> component,<br> the<br>fﬁcacy<br> of<br> FluBlok<br> was<br> greater<br> against<br> CDC-ILI<br> due<br> to<br> inﬂuenza<br> A<br>iruses<br> (54.4%)<br> than<br> inﬂuenza<br> B<br> viruses<br> (23.1%),<br> although<br> the<br> differ-<br>nce<br> was<br> not<br> statistically<br> signiﬁcant<br> (P<br> =<br> .20<br> by<br> logistic<br> regression).<br>owever,<br> we  were<br> not<br> able<br> to<br> demonstrate<br> a<br> statistically<br> signiﬁcant<br>ffect<br> for<br> inﬂuenza<br> B.<br> As<br> shown<br> in<br> Table<br> 3,<br> there<br> were<br> no<br> sub-<br>tantial<br> differences<br> between<br> the<br> point<br> estimates<br> of<br> efﬁcacy<br> against<br>ulture<br> positive<br> CDC-ILI<br> or<br> against<br> any<br> culture<br> positive<br> illness.<br> Cul-<br>ure<br> positive<br> CDC-ILI<br> associated<br> with<br> isolation<br> of<br> H1N1<br> viruses<br>ccurred<br> in<br> 9/2304<br> placebo<br> recipients<br> and<br> 3/2344<br> FluBlok<br> recip-<br>ents<br> (PE<br> =<br> 67%),<br> while<br> culture<br> positive<br> CDC-ILI<br> due<br> to<br> H3N2<br> viruses</div>
</div>
<div class="page">
<h2>Page 5</h2>
<div class="figure">
<img src="figures/figure_p5_c2fc83df.png" alt="[FIGURE 1 - See figure_p5_c2fc83df.png]" style="max-width: 800px;">
<div class="figure-caption">[FIGURE 1 - See figure_p5_c2fc83df.png]</div>
</div>
<div class="text">e<br> to<br> inﬂuenza<br> A<br> (A)<br> and<br> inﬂuenza<br> B<br> (B)<br> in<br> the<br> placebo<br> (solid<br> line)<br> and<br> FluBlok<br>otted<br> line)<br> groups<br> by<br> date<br> during<br> the<br> surveillance<br> period.</div>
<div class="text">curred<br> in<br> 58/2304<br> placebo<br> and<br> in<br> 33/2344<br> FluBlok<br> recipients<br>E<br> =<br> 44%).<br> Overall<br> CDC-ILI<br> regardless<br> of<br> culture<br> results<br> occurred<br> in<br>62<br> (7.0%)<br> of<br> placebo<br> recipients<br> and<br> 127<br> (5.4%)<br> of<br> FluBlok<br> recipients<br>r<br> an<br> efﬁcacy<br> of<br> 22.9%<br> (95%<br> CI,<br> 2.2%,<br> 39.4%)<br> against<br> this<br> outcome.</div>
<div class="title">None</div>
<div class="text">In this<br> prospective,<br> randomized<br> clinical<br> trial,<br> we  evaluated<br> the<br>fety,<br> immunogenicity<br> and<br> efﬁcacy<br> of<br> FluBlok,<br> a<br> trivalent<br> recombi-<br>ant<br> hemagglutinin<br> (rHA0)<br> vaccine.<br> The<br> vaccine<br> was<br> well<br> tolerated<br>healthy<br> adults,<br> immunogenic,<br> and<br> protective<br> against<br> culture<br> con-<br>rmed<br> inﬂuenza<br> illness.<br> The<br> safety<br> data<br> generated<br> in<br> this<br> study<br>e<br> consistent<br> with<br> the<br> safety<br> proﬁle<br> observed<br> in<br> other<br> studies<br> of</div>
<div class="title">tes
 of
 st</div>
<div class="text">ipients.<br>ndpoint<br>Number (%) of cases in those receiving<br>Vaccine efﬁcacy</div>
<div class="figure">
<img src="figures/table_p5_3dd7575f.png" alt="[TABLE 8 - See table_p5_3dd7575f.png]" style="max-width: 800px;">
<div class="figure-caption">[TABLE 8 - See table_p5_3dd7575f.png]</div>
</div>
<div class="text">consecutive<br> days.</div>
<div class="text">HA0<br> vaccine<br> produced<br> using<br> the<br> baculovirus<br> expression<br> system<br>n<br> healthy<br> adults<br> [9].  These<br> vaccines<br> have<br> been<br> well<br> tolerated<br> at<br> all<br>oses<br> administered,<br> and<br> are<br> associated<br> with<br> low<br> rates<br> of<br> local<br> reac-<br>ons.<br> One<br> case<br> of<br> pericarditis<br> was<br> detected<br> in<br> a<br> FluBlok<br> recipient.<br>ericarditis<br> has<br> also<br> been<br> reported<br> previously<br> following<br> vaccina-<br>on<br> with<br> licensed,<br> egg-derived<br> inﬂuenza<br> vaccine<br> with<br> a<br> similar<br>me<br> course<br> [11].<br> The<br> mechanism<br> and<br> clinical<br> signiﬁcance<br> of<br> such<br>n<br> association<br> is<br> unclear.<br>FluBlok<br> induced<br> serum<br> HAI<br> antibody<br> responses<br> to<br> all<br> three<br> vac-<br>ne<br> components<br> in<br> the<br> majority<br> of<br> recipients,<br> and<br> the<br> lower<br> limit<br>f<br> the<br> 95%<br> conﬁdence<br> interval<br> for<br> response<br> rate<br> exceeded<br> the<br> US<br>DA<br> criteria<br> for<br> licensure<br> for<br> all<br> three<br> components<br> (lower<br> limit<br> of<br>he<br> 95%<br> conﬁdence<br> interval<br> for<br> response<br> rate<br> >40%<br> and<br> lower<br> limit<br>f<br> the<br> 95%<br> conﬁdence<br> interval<br> for<br> HAI<br> titer<br> of<br> 1:40<br> or<br> greater<br> >70%)<br>2].<br>Although<br> we<br> did<br> not<br> attempt<br> to<br> verify<br> vaccine<br> histories<br> by<br>eview<br> of<br> medical<br> records,<br> signiﬁcant<br> differences<br> in<br> both<br> the<br> fre-<br>uency<br> and<br> the<br> magnitude<br> of<br> the<br> HAI<br> response<br> were<br> shown<br> when<br>omparing<br> the<br> immune<br> response<br> between<br> subjects<br> with<br> self-<br>eported<br> previous<br> vaccination.<br> Reduced<br> antibody<br> response<br> rates,<br>ecreased<br> post<br> vaccination<br> titers,<br> and<br> decreased<br> antibody<br> secret-<br>ng<br> cell<br> responses<br> have<br> all<br> been<br> observed<br> previously<br> in<br> adults<br> with<br>rior<br> inﬂuenza<br> vaccine<br> compared<br> to<br> those<br> without<br> [13–16].<br> The<br>xact<br> mechanism<br> of<br> this<br> effect<br> remains<br> uncertain,<br> although<br> it<br> may<br>epresent<br> interference<br> with<br> antigen<br> presentation<br> by<br> pre-existing<br>ntibody<br> [16].<br>Consistent<br> with<br> the<br> results<br> of<br> national<br> surveillance<br> in<br> the<br> US<br>uring<br> the<br> 2007–2008<br> season<br> [17], the<br> majority<br> of<br> inﬂuenza<br> A<br>ruses<br> detected<br> in<br> this<br> study<br> were<br> H3N2<br> viruses<br> that<br> represented<br>substantial<br> antigenic<br> mismatch<br> with<br> the<br> vaccine.<br> However,<br> even<br>nder<br> these<br> circumstances,<br> FluBlok<br> had<br> signiﬁcant<br> protective<br> efﬁ-<br>acy<br> against<br> culture-conﬁrmed<br> inﬂuenza<br> illness,<br> including<br> those<br>meeting<br> the<br> CDC-ILI<br> case<br> deﬁnition.<br> Inﬂuenza<br> B<br> viruses<br> isolated<br> in<br>his<br> study<br> and<br> elsewhere<br> in<br> North<br> America<br> during<br> the<br> 2007–2008<br>eason<br> belonged<br> to<br> the<br> Yamagata<br> lineage<br> of<br> inﬂuenza<br> B<br> viruses,<br>gainst<br> which<br> vaccines<br> representing<br> the<br> Victoria<br> lineage<br> would<br> be<br>xpected<br> to<br> have<br> little<br> or<br> no<br> efﬁcacy.<br> We  also<br> found<br> that<br> the<br> efﬁ-<br>acy<br> of<br> FluBlok<br> against<br> CDC-ILI<br> associated<br> with<br> inﬂuenza<br> B<br> was<br>ubstantially<br> lower<br> than<br> that<br> against<br> inﬂuenza<br> A.<br>Comparisons<br> <br>of<br> <br>these<br> <br>results<br> <br>with<br> <br>the<br> <br>results<br> <br>of<br> <br>other<br>ssessments<br> of<br> the<br> protective<br> efﬁcacy<br> of<br> inﬂuenza<br> vaccines<br> are<br>omplicated<br> by<br> differences<br> in<br> methodologies,<br> populations,<br> and<br>ntigenic<br> match<br> between<br> vaccine<br> and<br> circulating<br> strains<br> in<br> the<br>peciﬁc<br> year<br> that<br> studies<br> are<br> carried<br> out.<br> Two<br> recently<br> published<br>udies<br> have<br> evaluated<br> egg-grown<br> inactivated<br> vaccines<br> in<br> healthy<br>dults<br> using<br> a<br> placebo-controlled<br> design<br> during<br> the<br> 2007–2008<br>nﬂuenza<br> season.<br> In<br> one<br> study,<br> conducted<br> primarily<br> in<br> Europe,<br> the<br>verall<br> efﬁcacy<br> of<br> egg-grown<br> inactivated<br> vaccine<br> against<br> culture<br>onﬁrmed<br> illness<br> was<br> 63%,<br> and<br> the<br> lower<br> 95%<br> CI<br> was<br> 46.7%<br> [18].<br> The<br>redominant<br> inﬂuenza<br> A<br> isolates<br> in<br> that<br> study<br> were<br> H1N1<br> viruses,<br>which<br> were<br> mostly<br> vaccine-like.<br> In<br> another<br> smaller<br> study<br> done<br> on<br>ollege<br> campuses<br> in<br> Michigan<br> [19], the<br> protective<br> efﬁcacy<br> of<br> TIV<br>gainst<br> culture<br> conﬁrmed<br> illness<br> was<br> 73%<br> (95%<br> CI,<br> 51%,<br> 85%).<br> In<br>hat<br> study,<br> 90%<br> of<br> inﬂuenza<br> isolates<br> were<br> inﬂuenza<br> A<br> (H3N2),<br> but<br>he<br> antigenic<br> characterization<br> of<br> isolates<br> was<br> not<br> reported.<br> In<br> other<br>ecent<br> randomized<br> trials,<br> the<br> protective<br> efﬁcacy<br> of<br> TIV<br> was<br> 22.3%<br>n<br> the<br> 2005–2006<br> inﬂuenza<br> season<br> predominated<br> by<br> inﬂuenza<br> B<br>ruses<br> and<br> with<br> overall<br> low<br> attack<br> rates<br> [20], and<br> 49.3%<br> over<br> two<br>easons,<br> 2005–2007<br> with<br> most<br> cases<br> due<br> to<br> antigenically<br> variant<br>ruses<br> [21].<br>Because<br> of<br> the<br> difﬁculty<br> in<br> conducting<br> placebo-controlled<br>udies<br> of<br> inﬂuenza<br> vaccine<br> especially<br> as<br> the<br> target<br> groups<br> for<br> vac-<br>nation<br> have<br> expanded,<br> several<br> recent<br> assessments<br> of<br> inﬂuenza<br>accine<br> effectiveness<br> have<br> utilized<br> a<br> test-negative,<br> case–control<br>esign.<br> Estimates<br> of<br> overall<br> inactivated<br> vaccine<br> protective<br> effec-<br>veness<br> in<br> these<br> studies<br> have<br> ranged<br> from<br> 10%<br> to<br> 70%<br> [22–25]<br> and</div>
</div>
<div class="page">
<h2>Page 6</h2>
<div class="text">y<br>p<br>y<br>g<br>irculating<br> viruses,<br> with<br> highest<br> levels<br> of<br> effectiveness<br> reported<br> for<br>H1<br> viruses<br> [25]<br> and<br> lowest<br> levels<br> for<br> inﬂuenza<br> B.<br>The<br> current<br> study<br> provides<br> evidence<br> of<br> protective<br> efﬁcacy<br> of<br>baculovirus-derived<br> HA<br> vaccine<br> in<br> adults<br> for<br> prevention<br> of<br> sea-<br>onal<br> inﬂuenza<br> and<br> supports<br> that<br> signiﬁcant<br> protection<br> in<br> a<br> primed<br>opulation<br> can<br> be<br> obtained<br> against<br> inﬂuenza<br> with<br> a<br> pure<br> hemag-<br>lutinin<br> vaccine.<br> The<br> efﬁcacy<br> results<br> also<br> demonstrate<br> that<br> in<br>dults,<br> the<br> minor<br> differences<br> in<br> HA<br> glycosylation<br> seen<br> in<br> insect<br> cells<br>ompared<br> to<br> mammalian<br> cells<br> and<br> the<br> synthesis<br> of<br> the<br> HA<br> as<br> an<br>ncleaved<br> precursor<br> do<br> not<br> preclude<br> the<br> generation<br> of<br> an<br> effective<br>mmune<br> response<br> in<br> adults.<br>The<br> use<br> of<br> recombinant<br> DNA<br> techniques<br> to<br> express<br> proteins<br>n<br> cell<br> culture<br> has<br> been<br> a<br> successful<br> approach<br> for<br> generation<br> of<br>ighly<br> effective<br> vaccines<br> for<br> the<br> prevention<br> of<br> hepatitis<br> B<br> (HBV)<br>nd<br> human<br> papillomavirus<br> (HPV),<br> and<br> baculovirus<br> expression<br> tech-<br>ology<br> is<br> currently<br> used<br> for<br> a<br> licensed<br> HPV<br> vaccine<br> [26].<br> Among<br>he<br> available<br> expression<br> technologies,<br> recombinant<br> baculovirus<br> is<br>specially<br> well<br> suited<br> for<br> production<br> of<br> inﬂuenza<br> vaccine<br> because<br>he<br> rapidity<br> with<br> which<br> genes<br> can<br> be<br> cloned<br> and<br> inserted<br> into<br> this<br>ector<br> facilitates<br> updating<br> the<br> vaccine<br> at<br> regular<br> intervals.<br> Expres-<br>ion<br> of<br> the<br> HA<br> protein<br> in<br> insect<br> cells<br> using<br> recombinant<br> baculovirus<br>lso<br> avoids<br> the<br> need<br> to<br> work<br> with<br> potentially<br> pathogenic,<br> live<br>nﬂuenza<br> viruses,<br> and<br> the<br> attendant<br> biocontainment<br> issues<br> that<br>would<br> be<br> a<br> particular<br> concern<br> for<br> production<br> of<br> pandemic<br> vaccines<br>27].<br> The<br> results<br> of<br> the<br> current<br> study<br> support<br> the<br> utility<br> of<br> insect<br>ells<br> for<br> the<br> production<br> of<br> well<br> tolerated<br> and<br> effective<br> vaccines<br> for<br>easonal<br> inﬂuenza.</div>
<div class="title">g</div>
<div class="text">g<br>y<br>g<br>,<br>Fleur,<br> Anthony<br> Meyer<br> and<br> Adam<br> Gilbert,<br> and<br> the<br> effort<br> of<br> inves-<br>gators<br> at<br> the<br> study<br> sites<br> listed<br> below.<br>St d<br>it<br>Th f ll<br>i<br>i<br>ti<br>t<br>d t d<br>it<br>ll d</div>
<div class="text">Study<br> sites:<br> The<br> following<br> investigators<br> and<br> study<br> sites<br> enrolled<br>bjects<br> in<br> this<br> study:<br> Mhorag<br> Hay<br> M.D.,<br> University<br> of<br> Rochester<br>hool<br> of<br> Medicine,<br> Rochester,<br> NY;<br> Mark<br> Blatter<br> M.D.,<br> Primary<br>hysicians<br> Research,<br> Pittsburgh,<br> PA;<br> Stanley<br> Block<br> M.D.,<br> Kentucky<br>diatric/Adult<br> Research,<br> Bardstown,<br> KY;<br> Bruce<br> Bowling<br> M.D.,<br>egional<br> Clinical<br> Research,<br> Endwell,<br> NY;<br> Teresa<br> Coats<br> M.D.,<br> Bench-<br>ark<br> Research,<br> Austin,<br> TX;<br> Hana<br> El<br> Sahly<br> M.D.,<br> Baylor<br> College<br> of<br>edicine,<br> Houston,<br> TX;<br> Ivor<br> Emanuel<br> M.D.,<br> Benchmark<br> Research,<br>n<br> Francisco,<br> CA;<br> Brandon<br> Essink<br> M.D.,<br> Meridian<br> Clinical<br> Research,<br>maha,<br> NB;<br> Larry<br> Gilderman<br> D.O.,<br> University<br> Clinical<br> Research<br>mbroke,<br> Pines,<br> FL;<br> Irene<br> Graham<br> M.D.,<br> St.<br> Louis<br> University,<br> St.<br>uis,<br> MO;<br> Matt<br> Hall<br> M.D.,<br> Marshﬁeld<br> Clinic,<br> Marshﬁeld,<br> WI;<br> Lydie<br>azan<br> M.D.,<br> Impact<br> Clinical<br> Trials,<br> Beverly<br> Hills,<br> CA;<br> Darrell<br> Her-<br>ngton<br> D.O.,<br> Benchmark<br> Research,<br> San<br> Angelo,<br> TX;<br> Steven<br> Hull<br>.D.,<br> Vince<br> and<br> Associates<br> Clinical<br> Research,<br> Overland<br> Park,<br> KS;<br>obert<br> Jeanfreau<br> M.D.,<br> Benchmark<br> Research<br> Metairie,<br> LA;<br> James<br>ng<br> M.D.,<br> University<br> of<br> Maryland,<br> Baltimore,<br> MD;<br> Ivan<br> Rarick<br>.D.,<br> Benchmark<br> Research,<br> Sacramento,<br> CA;<br> Keith<br> Reisinger<br> M.D.,<br>imary<br> Physicians<br> Research,<br> Pittsburgh,<br> PA;<br> Robert<br> Rosen<br> M.D.,<br>arolina<br> Medical<br> Trials,<br> Winston-Salem,<br> NC;<br> Gilbert<br> Schiff<br> M.D.,<br>erling<br> Research,<br> Cincinnati,<br> OH;<br> William<br> Seger<br> M.D.,<br> Benchmark<br>esearch<br> Fort,<br> Worth,<br> TX;<br> Helen<br> Keipp<br> Talbot<br> M.D.,<br> Vanderbilt<br> Uni-<br>rsity,<br> Nashville,<br> TN;<br> Gilbert<br> Podolsky<br> M.D.,<br> Jean<br> Brown<br> Research<br>lt,<br> Lake<br> City,<br> UT;<br> Birgit<br> Winther<br> M.D.,<br> University<br> of<br> Virginia,<br> Char-<br>ttesville,<br> VA.<br>Conﬂict<br> of<br> interest<br> statement:<br> J.T.<br> has<br> received<br> grant<br> support<br> for<br>nical<br> trials<br> from<br> Protein<br> Sciences<br> Corporation,<br> Wyeth,<br> Sanoﬁ,<br>axoSmithKline,<br> PaxVax,<br> Ligocyte,<br> and<br> Vaxinnate,<br> and<br> is<br> a<br> paid<br>nsultant<br> to<br> ITS<br> incorporated<br> and<br> Novartis.<br> H.E.-S.<br> has<br> received<br>ant<br> support<br> from<br> GlaxoSmithKline<br> for<br> clinical<br> trials.<br> I.G.,<br> and<br>K.<br> report<br> no<br> conﬂicts<br> of<br> interest.<br> P.P.<br> and<br> R.K.<br> are<br> paid<br> consul-</div>
<div class="text">nts<br> to<br> Protein<br> Sciences<br> and<br> multiple<br> other<br> entities.<br> R.I.<br> and<br> M.C.<br>e<br> employees<br> of<br> Protein<br> Sciences.<br> Financial<br> support: The<br> study<br>as<br> funded<br> by<br> Protein<br> Sciences<br> Corporation,<br> the<br> manufacturers<br>the<br> vaccine.<br> Protein<br> Sciences<br> Corporation<br> also<br> funded<br> ICON<br> as<br>e<br> CRO<br> for<br> the<br> study<br> and<br> Ockham<br> which<br> performed<br> the<br> data<br>nalysis.</div>
<div class="title">None</div>
<div class="text">grown<br> in<br> mammalian<br> cells<br> or<br> embryonated<br> eggs.<br> J Infect<br> Dis<br> 1989;160:191–8.<br>2]<br> Wood<br> JM,<br> Oxford<br> JS,<br> Dunleavy<br> U,<br> Newman<br> RW,<br> Major<br> D,<br> Robertson<br> JS.<br> Inﬂuenza<br>A(H1N1)<br> vaccine<br> efﬁcacy<br> in<br> animal<br> models<br> is<br> inﬂuenced<br> by<br> two<br> amino<br> acid<br>substitutions<br> in<br> the<br> hemagglutinin<br> molecule.<br> Virology<br> 1989;171:214–21.<br>3]  Powers<br> DC,<br> Smith<br> GE,<br> Anderson<br> EL,<br> Kennedy<br> DJ,<br> Hackett<br> CS,<br> Wilkinson<br> BE,<br> et<br> al.<br>Inﬂuenza<br> A<br> virus<br> vaccines<br> containing<br> puriﬁed<br> recombinant<br> H3<br> hemagglutinin<br>are<br> well-tolerated<br> and<br> induce<br> protective<br> immune<br> responses<br> in<br> healthy<br> adults.<br>J<br> Infect<br> Dis<br> 1995;171:1595–8.<br>4] Lakey<br> DL,<br> Treanor<br> JJ,<br> Betts<br> RF,<br> Smith<br> GE,<br> Thompson<br> J,<br> Sannella<br> E,<br> et<br> al.<br> Recom-<br>binant<br> baculovirus<br> inﬂuenza<br> A<br> hemagglutinin<br> vaccines<br> are<br> well<br> tolerated<br> and<br>immunogenic<br> in<br> healthy<br> adults.<br> J Infect<br> Dis<br> 1996;174:838–41.<br>5] Treanor<br> JJ,<br> Betts<br> RF,<br> Smith<br> GE,<br> Anderson<br> EL,<br> Hackett<br> CS,<br> Wilkinson<br> BE,<br> et<br> al.<br> Eval-<br>uation<br> of<br> a<br> recombinant<br> hemagglutinin<br> expressed<br> in<br> insect<br> cells<br> as<br> an<br> inﬂuenza<br>vaccine<br> in<br> young<br> and<br> elderly<br> adults.<br> J Infect<br> Dis<br> 1996;173:1467–70.<br>6] Baxter<br> R,<br> Patriarca<br> PA,<br> Ensor<br> K,<br> Izikson<br> R,<br> Goldenthal<br> KL,<br> Cox<br> MM.<br> Reacto-<br>genicity<br> and<br> immunogenicity<br> of<br> FluBlok<br> trivalent<br> recombinant<br> baculovirus-<br>expressed<br> hemagglutinin<br> vaccine<br> administered<br> intramuscularly<br> to<br> healthy<br>adults<br> 50–64<br> years<br> of<br> age.<br> Vaccine<br> 2011;29:2272–8.<br>7]<br> Treanor<br> JJ,<br> Schiff<br> GM,<br> Couch<br> RB,<br> Cate<br> TR,<br> Brady<br> RC,<br> Hay<br> CM,<br> et<br> al.<br> Dose-related<br>safety<br> and<br> immunogenicity<br> of<br> a<br> trivalent<br> baculovirus-expressed<br> inﬂuenza-<br>virus<br> hemagglutinin<br> vaccine<br> in<br> elderly<br> adults.<br> J Infect<br> Dis<br> 2006;193:1223–8.<br>8]<br> Keitel<br> WA,<br> Treanor<br> J,<br> El<br> Sahly<br> HM,<br> Gilbert<br> A,<br> Maeyer<br> AL,<br> Patricarca<br> PA,<br> et<br> al.<br>Comparative<br> immunogenicity<br> of<br> recombinant<br> inﬂuenza<br> hemagglutinin<br> (rHA)<br>and  trivalent<br> inactivated<br> vaccines<br> (TIV)<br> among<br> persons<br> ><br> 65<br> years<br> old.<br> Vaccine<br>2009;28:379–85.<br>9] Treanor<br> JJ,<br> Schiff<br> GM,<br> Hayden<br> FG,<br> Brady<br> RC,<br> Hay<br> CM,<br> Meyer<br> AL,<br> et<br> al.<br> Safety<br> and<br>immunogenicity<br> of<br> a<br> baculovirus-expressed<br> hemagglutinin<br> inﬂuenza<br> vaccine:<br>a  randomized<br> controlled<br> trial.<br> JAMA<br> 2007;297:1577–82.<br>0] CDC.<br> Prevention<br> and<br> control<br> of<br> inﬂuenza:<br> recommendations<br> of<br> the<br> Advisory<br>Committee<br> on<br> Immunization<br> Practice<br> (ACIP),<br> 2007.<br> MMWR<br> Morb<br> Mortal<br> Wkly<br>Rep  2007;56:1–40.<br>1]<br> Meester<br> A,<br> Luwaert<br> R,<br> Chaudron<br> JM.<br> Symptomatic<br> pericarditis<br> after<br> inﬂuenza<br>vaccination:<br> report<br> of<br> two<br> cases.<br> Chest<br> 2000;117:1803–5.<br>2] FDA.<br> Guidance<br> for<br> industry:<br> clinical<br> data<br> needed<br> to<br> support<br> the<br> licensure<br> of<br>seasonal<br> inactivated<br> inﬂuenza<br> vaccines;<br> 2007.<br>3]<br> Beyer<br> WEP,<br> Palache<br> AM,<br> Sprenger<br> MJW,<br> Hendriksen<br> E,<br> Tukker<br> JJ,<br> Darioli<br> R,<br> et<br> al.<br>Effects<br> of<br> repeated<br> annual<br> inﬂuenza<br> vaccination<br> on<br> vaccine<br> sero-response<br> in<br>young and<br> elderly<br> adults.<br> Vaccine<br> 1996;14:1331–9.<br>4]<br> Goodwin<br> K,<br> Viboud<br> C,<br> Simonsen<br> L.<br> Antibody<br> response<br> to<br> inﬂuenza<br> vaccination<br>in<br> the<br> elderly:<br> a<br> quantitative<br> review.<br> Vaccine<br> 2006;24:1159–69.<br>5] Engler<br> RJ,<br> Nelson<br> MR,<br> Klote<br> MM,<br> Van<br> Raden<br> MJ,<br> Huang<br> CY,<br> Cox<br> NY,<br> et<br> al.<br> Half-<br> vs<br>full-dose<br> trivalent<br> inactivated<br> inﬂuenza<br> vaccine<br> (2004–2005):<br> age,<br> dose,<br> and<br>sex effects<br> on<br> immune<br> responses.<br> Arch<br> Intern<br> Med<br> 2008;168:2405–14.<br>6]<br> Sasaki<br> S,<br> He<br> X-S,<br> Holmes<br> TH,<br> Dekker<br> CL,<br> Kemble<br> GW,<br> Arvin<br> AM,<br> et<br> al.<br> Inﬂu-<br>ence<br> of<br> prior<br> inﬂuenza<br> vaccination<br> on<br> antibody<br> and<br> B-Cell<br> responses.<br> PLoS<br> One<br>2008;3:e2975.<br>7] CDC.<br> Inﬂuenza<br> activity—United<br> States<br> and<br> worldwide,<br> 2007–08<br> season.<br> MMWR<br>Morb<br> Mortal<br> Wkly<br> Rep<br> 2008:57.<br>8]<br> Frey<br> S,<br> Vesikari<br> T,<br> Szymczakiewicz-Multanowska<br> A,<br> Lattanzi<br> M,  Izu<br> A,<br> Groth<br>N,<br> et<br> al.<br> Clinical<br> efﬁcacy<br> of<br> cell<br> culture-derived<br> and<br> egg-derived<br> inactivated<br>subunit<br> inﬂuenza<br> vaccines<br> in<br> healthy<br> adults.<br> Clin<br> Infect<br> Dis<br> 2010;51:997–1004.<br>9]<br> Monto<br> AS,<br> Ohmit<br> SE,<br> Petrie<br> JG,<br> Johnson<br> E,<br> Truscon<br> R,<br> Teich<br> E,<br> et<br> al.<br> Comparative<br>efﬁcacy<br> of<br> inactivated<br> and<br> live<br> attenuated<br> inﬂuenza<br> vaccines.<br> N<br> Engl<br> J Med<br>2009;361:1260–7.<br>0] Beran<br> J,<br> Wertzova<br> V,<br> Honegr<br> K,<br> Kaliskova<br> E,<br> Havlickova<br> M,<br> Havlik<br> J, et<br> al.<br>Challenge<br> of<br> conducting<br> a<br> placebo-controlled<br> randomized<br> efﬁcacy<br> study<br> for<br>inﬂuenza<br> vaccine<br> in<br> a<br> season<br> with<br> low<br> attack<br> rate<br> and<br> a mismatched<br> vaccine<br> B<br>strain:<br> a<br> concrete<br> example.<br> BMC<br> Infect<br> Dis<br> 2009;9:2.<br>1]<br> Jackson<br> L,<br> Gaglani<br> M,  Keyserling<br> H,<br> Balser<br> J, Bouveret<br> N,<br> Fries<br> L,<br> et<br> al.<br> Safety,<br>efﬁcacy,<br> and<br> immunogenicity<br> of<br> an<br> inactivated<br> inﬂuenza<br> vaccine<br> in<br> healthy<br>adults:<br> a<br> randomized,<br> placebo-controlled<br> trial<br> over<br> two<br> inﬂuenza<br> seasons.<br> BMC<br>Infect<br> Dis<br> 2010;10:71–7.<br>2]<br> Belongia<br> EA,<br> Kieke<br> BA,<br> Donahue<br> JG,<br> Greenlee<br> RT,<br> Balish<br> A,<br> Foust<br> A,<br> et<br> al.<br>Effectiveness<br> of<br> inactivated<br> inﬂuenza<br> vaccines<br> varied<br> substantially<br> with<br> anti-<br>genic<br> match<br> from<br> the<br> 2004–2005<br> season<br> to<br> the<br> 2006–2007<br> season.<br> J<br> Infect<br> Dis<br>2009:199.<br>3]<br> Skowronski<br> DM,<br> Masaro<br> C,<br> Kwindt<br> TL,<br> Mak<br> A,<br> Petric<br> M,  Li<br> Y,<br> et<br> al.<br> Estimating<br>vaccine<br> effectiveness<br> against<br> laboratory-conﬁrmed<br> inﬂuenza<br> using<br> a sentinel<br>physician<br> network:<br> Results<br> from<br> the<br> 2005–2006<br> season<br> of<br> dual<br> A<br> and<br> B<br> vaccine<br>mismatch<br> in<br> Canada.<br> Vaccine<br> 2007;25:2842–51.<br>4]<br> Belongia<br> E,<br> Kieke<br> B,<br> Coleman<br> L,<br> Donahue<br> J,<br> Irving<br> S,<br> Meece<br> J, et<br> al.<br> Interim<br>within-season<br> estimate<br> of<br> the<br> effectiveness<br> of<br> trivalent<br> inactivated<br> inﬂuenza</div>
</div>
<div class="page">
<h2>Page 7</h2>
<div class="text">Mortal<br> Wkly<br> Rep<br> 2008;57:393–8.<br>Skowronski<br> DM,<br> De<br> Serres<br> G,<br> Dickinson<br> J,<br> Petric<br> M,<br> Mak<br> A,<br> Fonseca<br> K,<br> et<br> al.<br>Component-speciﬁc<br> effectiveness<br> of<br> trivalent<br> inﬂuenza<br> vaccine<br> as<br> monitored<br>through<br> a<br> sentinel<br> surveillance<br> network<br> in<br> Canada,<br> 2006–2007.<br> J<br> Infect<br> Dis<br>2009;199:160–79.</div>
<div class="text">]<br>p<br>J<br>Efﬁcacy<br> of<br> a<br> bivalent<br> L1<br> virus-like<br> particle<br> vaccine<br> in<br> prevention<br> of<br> infection<br>with human<br> papillomavirus<br> types<br> 16<br> and<br> 18<br> in<br> young<br> women:<br> a<br> randomised<br>controlled<br> trial.<br> Lancet<br> 2004;364:1757–65.<br>]<br> Treanor<br> JJ.<br> Recombinant<br> proteins<br> produced<br> in<br> insect<br> cells.<br> Curr<br> Top<br> Microbiol<br>Immunol<br> 2009;333:211–25.</div>
</div>
<div class="metadata">
<h3>Extraction Metadata</h3>
<p>Text blocks: 56</p>
<p>Figures/Tables: 6</p>
</div>

</body>
</html>
